BrainStorm Cell Therapeutics Inc. (BCLI) stock
Close on Oct 19, 2026Market cap $8.50MP/E –Yield –
BrainStorm Cell Therapeutics statistics
24 measures from SEC filings and the closing price. Hover a name for the formula; the last column is the median of companies in the same industry group.
Important dates
- Next earnings
- –
- Last ex-dividend date
- No dividends
- Fundamentals through
- Jun 30, 2026
- Share price as of
- –
Share statisticsIndustry
- Shares Change (YoY)
- 69.9%
- 10.9%
- Shares Change (QoQ)
- 0.00%
- 0.50%
- Float
- 8M
- 49M
- Shares Held by Insiders
- 29.6%
- 11.6%
Returns on capitalIndustry
- Return on Assets (ROA)
- -627.4%
- -40.2%
Financial positionIndustry
- Current Ratio
- 0.03
- 3.30
- Quick Ratio
- 0.00
- 2.39
EfficiencyIndustry
- Profits Per Employee
- -$526.10K
- -$680.43K
- Employee Count
- 20
- 75
Income statement (TTM)Industry
Balance sheetIndustry
- Net Cash (Debt)
- -$1.24M
- $16.33M
- Net Cash Per Share
- -$0.11
- $0.72
- Equity (Book Value)
- -$11.60M
- $53.27M
- Book Value Per Share
- -$1.05
- $1.49
- Tangible Book Value
- -$11.60M
- $26.53M
- Working Capital
- -$12.07M
- $77.95M
Cash flow (TTM)Industry
Scores and fair valueIndustry
- Piotroski F-Score
- 2
- 4
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Oct 19, 2026. The S&P 500 is measured by the SPY fund.
| Period | BCLI | S&P 500 | Difference | BCLI per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -14.4% | +0.6% | −15.1 pts | ||
| 3 months | -14.1% | +3.4% | −17.5 pts | ||
| Year to date | +39.2% | +13.3% | +26.0 pts | ||
| 1 year | +18.5% | +16.6% | +1.9 pts | ||
| 3 years | -74.3% | +86.4% | −160.7 pts | -36.4% | +23.1% |
| 5 years | -98.4% | +81.9% | −180.2 pts | -56.1% | +12.7% |
| 10 years | -97.8% | +318.9% | −416.6 pts | -31.7% | +15.4% |
Short interest
Shares sold short and not yet covered, reported by brokers to FINRA twice a month. Latest settlement date Oct 30, 2026.
0M BCLI shares were sold short on Oct 30, 2026, up 76.9% from the previous report. At recent volumes it would take 2.0 days to buy them back. Over the last 20 sessions, 58.2% of the volume reported to FINRA was short selling.
| Settlement date | Shares short | Change | Avg. daily volume | Days to cover |
|---|---|---|---|---|
| Oct 30, 2026 | 60,573 | +76.9% | 30,082 | 2.0 |
| Oct 15, 2026 | 34,232 | -6.1% | 23,350 | 1.5 |
| Sep 30, 2026 | 36,461 | -14.1% | 25,299 | 1.4 |
| Sep 15, 2026 | 42,444 | -13.5% | 31,374 | 1.4 |
| Aug 31, 2026 | 49,072 | +2.8% | 109,033 | 1.0 |
| Aug 14, 2026 | 47,737 | +1.5% | 50,105 | 1.0 |
| Jul 31, 2026 | 47,029 | +3.0% | 18,993 | 2.5 |
| Jul 15, 2026 | 45,668 | -22.2% | 105,938 | 1.0 |
| Jun 30, 2026 | 58,736 | -0.7% | 22,462 | 2.6 |
| Jun 15, 2026 | 59,174 | +9.0% | 30,791 | 1.9 |
| May 29, 2026 | 54,300 | +1.7% | 22,784 | 2.4 |
| May 15, 2026 | 53,390 | +0.2% | 13,168 | 4.0 |
Ratios use trailing-twelve-month results and the latest balance sheet. How we calculate.
See a number that looks wrong?